Overview

Gender

male

Jeffrey D. Kent is the Executive Vice President of Medical Affairs and Outcomes Research at Horizon Pharma. Most recently, Dr. Kent was executive director, medical affairs at Astellas Pharmaceuticals. Prior to Astellas, he spent over 8 years at Abbott as global project head, immunology medical affairs, where he created and led the immunology global medical affairs organization and played a key role in the successful launch and growth of HUMIRA®, Abbott's multi-indication blockbuster biologic for rheumatoid arthritis and other autoimmune disorders, which exceeded $8 billion in 2011 sales. In this role, Dr. Kent's responsibilities included building and organizing the medical affairs organization to focus globally on scientific communications and training, post-approval clinical trials, business development assessments, and external relations. Dr. Kent also worked at Searle Pharmaceuticals from 1999 to 2003, where he participated in the development of several blockbuster COX-2 inhibitors including CELEBREX® and BEXTRA®. While at Searle, Dr. Kent was a key contributor to multiple clinical trials, regulatory submissions, and publications and was promoted to the position of Clinical Program Director, leading the global development program of BEXTRA.

Dr. Kent completed medical school at Jefferson Medical College and completed his residency training in internal medicine at the Thomas Jefferson University Hospital in Philadelphia. Subsequently, Dr. Kent trained in gastroenterology and hepatology at Rush Presbyterian-St. Luke's Medical Center in Chicago. After completing his fellowship, he joined the faculty in the Department of Medicine, Section of Digestive Diseases at RUSH. Dr. Kent subsequently served as Associate Director of the Evanston Hospital Clinical Pharmacology Unit where he obtained experience with Phase I clinical trials with specific emphasis on ADME and first-in-human clinical trials.